MAY-HEALTH
May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it is changing its name from AblaCare to May Health, and has solidified its executive team with Anne Morrissey as CEO and Dr. Robert Auerbach, OBGYN, as chairman of the board. Morrissey, an experienced executive who was previously CEO of Alydia Health, will lead May Health as it investigates its novel Ovarian Rebalancing™ technology, a one-time, transvaginal ablation procedure designed to activate natural ovulation for those with PCOS, a leading cause of infertility.
“With Anne and Bob, May Health is guided by some of the most respected and accomplished leaders in the women's health care ecosystem,” said Antoine Papiernik, chairman and managing partner at Sofinnova Partners, and the previous chairman of May Health. “Anne is an experienced executive and team builder who has devoted her career to making pregnancy and childbirth safer and more accessible. As an OBGYN and retired president of CooperSurgical, Bob brings both clinical and operational expertise to the board. With their leadership, May Health is well positioned to enter a new phase of growth to develop and commercialize life-changing solutions for those living with PCOS.”
May Health’s proprietary technology, Ovarian Rebalancing, is an investigational treatment designed to start a woman’s natural ovulation cycle, allowing for the opportunity to become pregnant. It is an ultrasound-guided, transvaginal ablation procedure similar to egg retrieval that utilizes radiofrequency (RF) energy to establish regular menstrual cycles. Ovarian Rebalancing is a one-time, in-office procedure intended to allow for same-day recovery and return to normal activities. It is currently being investigated in a European clinical study and a U.S. feasibility study.
“Those with PCOS face significant health challenges and frustrations every day, from symptoms like weight gain and acne to irregular menstrual cycles and life-altering complications around ovulation and fertility,” said Dr. Auerbach. “The current fertility treatment landscape can be just as distressing for patients with concerns regarding cost, access, and the complexity of in vitro fertilization (IVF), along with side-effects of gonadotropins. Our goal is to develop a safe, simple procedure that activates natural ovulation for women living with PCOS. Ovarian Rebalancing has the potential to fill that need and help thousands of women regain the option to have children and start families, and we look forward to continuing to enroll patients in our clinical trials to demonstrate these benefits.”
“I joined May Health to change the outlook for people living and struggling with the negative effects of PCOS,” said Morrissey. “Restoring ovulation is our current focus, but our technology may also have the potential to address the underlying endocrine disorder. Our new name reflects this overarching commitment to helping women overcome PCOS and experience new beginnings and opportunities. I’m excited to lead and build a team that has the experience, passion, and empathy needed to improve the PCOS outlook for millions of women.”
About Polycystic ovary syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is a common endocrine condition where the ovaries produce abnormal levels of androgens, which are male sex hormones that are usually present in women in small amounts.1 In many cases, those with PCOS are unable to produce enough of the hormones needed to ovulate and become pregnant, which can lead to the development of ovarian cysts.1 PCOS is one of the most common causes of female infertility, affecting roughly 6 to 12% of U.S. women of reproductive age.2 PCOS is also a lifelong challenge that goes beyond fertility issues. Women with PCOS are often insulin resistant, increasing their risk for Type 2 diabetes; more than half of PCOS sufferers will develop Type 2 diabetes by age 40 and they are also at increased risk of heart disease and stroke.2 Other common, persistent symptoms of PCOS include irregular menstruation, acne, thinning scalp, excess hair growth on the face and body, high blood pressure, and sleep apnea.2
About Anne Morrissey
Anne Morrissey is an experienced entrepreneur, executive, and advisor who has led numerous medical device companies dedicated to women’s and maternal health care. Anne’s lifelong passion for making childbirth and motherhood safer and more accessible has led to leadership and advisory roles in numerous companies. She is the former Chair, President and CEO of Alydia Health, and serves as director of Femasys Inc.; she previously served as vice president of Astia; as co-founder and director of Vivant Medical; and as entrepreneur in residence of UCSF Innovation Ventures. Anne is a gifted team builder and manager who has led various exits, transitions, and global partnerships; she is an advisor to several prominent medtech CEOs and was named one of the 100 Women of MedTech in 2019.
About Dr. Robert Auerbach
Dr. Robert “Bob” Auerbach, OBGYN, has exemplified commitment to women’s and maternal health over a distinguished 35+ year career that includes both clinical practice and extensive experience running large healthcare companies. Dr. Auerbach served as the chief medical officer, chief strategy officer, and ultimately president of CooperSurgical, a wholly owned subsidiary of The Cooper Companies specializing in women’s healthcare and fertility treatments. He serves as the chairman of the board for Escala Medical, and as a board member for OCON Healthcare, Aspira Women’s Health, Empress Medical, and the Yale University Center for Biomedical Innovation and Technology. Dr. Auerbach is a graduate of the Lehigh-Hahnemann/Drexel 6-year BA-MD program and completed his OB/GYN residency at Yale, where he currently serves as an adjunct member of the medical school faculty.
About May Health
May Health, formerly AblaCare, is a clinical-stage medical device company committed to developing more treatment options for people living with PCOS. The company is currently investigating its Ovarian Rebalancing™ technology in clinical studies; Ovarian Rebalancing is a novel approach to PCOS-related fertility issues that has the potential to be a safe, relatively simple option for activating natural ovulation. May Health is led by a team of serial medtech and women’s health entrepreneurs and executives with extensive experience in product development, validation, and launch. The company has raised €10M in a Series A led by Sofinnova Partners and was founded in 2017 by the firm’s medtech acceleration team, Sofinnova MD Start. May Health is headquartered in Paris, France. For more information, visit www.mayhealth.com.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, visit: sofinnovapartners.com.
____________________
1 Johns Hopkins Medicine
2 CDC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirion Partners with IAEA to Enhance Radiation Safety on a Global Scale16.9.2025 23:19:00 CEST | Press release
Partnership Agreement to Strengthen Radiation Detection and Measurement Capabilities at the Terrestrial Environmental Radiochemistry (TERC) Laboratory, Safeguarding the Environment and Promoting Nuclear Safety Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, has signed a partnership agreement and practical arrangements with the International Atomic Energy Agency (IAEA), the world’s central intergovernmental forum for scientific and technical cooperation in the nuclear field, to cooperate in the area of radiation detection and measurement. Through this collaboration, Mirion’s advanced instrumentation and profound understanding of ionizing radiation will combine with the IAEA’s expertise and influence to advance the safe and secure use of nuclear technology worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916693003/en/ Mirion Chairman of the Board and CEO Thomas Logan and IAEA Director
NIQ and Displayce Collaborate to Bring Sales Lift Measurement to Europe’s DOOH Advertising Market16.9.2025 18:00:00 CEST | Press release
NIQ, a leading consumer intelligence company, and Displayce, a pioneering specialist technology suite for Out-of-Home advertising, are collaborating to bring advanced measurement capabilities to the European DOOH market. By combining NIQ’s trusted consumer intelligence with data from Displayce’s media activation platform, advertisers can link DOOH campaigns to in-store sales performance — driving transparency and accountability across the DOOH ecosystem. NIQ has long been a trusted source of consumer purchase insights for manufacturers and retailers, capturing the buying behavior of millions of households across more than 90 countries. Now, NIQ is extending its expertise and insights into the media ecosystem, empowering advertisers and agencies with new data assets and measurement solutions to improve their understanding of consumers and drive better ROI. Through the collaboration, NIQ and Displayce are driving the DOOH ecosystem toward more addressable, transparent, and results-driven
Capcom’s Resident Evil Requiem, the Latest Title in the Series, Also Coming to Nintendo Switch 2 on February 27, 2026!16.9.2025 15:00:00 CEST | Press release
– Additionally, two other Resident Evil series titles to be released for the console on the same date in step with Capcom’s multi-platform strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series scheduled for release on February 27, 2026, for PlayStation®5 system, Xbox Series X|S, and PC, will also be released for Nintendo Switch™ 2 at launch. In addition, Resident Evil 7 biohazard and Resident Evil Village, two other titles in the series, will also be released for Nintendo Switch 2 on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916064724/en/ Resident Evil Requiem Key Art Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development experience cultivated over numerou
Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production16.9.2025 15:00:00 CEST | Press release
Human insight and autonomous agents work together to transform operations, enhance efficiency, improve safety, and unlock new value across the enterprise. Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/ Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectiv
GlobalPlatform to Drive Next Phase of Growth for PSA Certified, Accelerating Security Adoption16.9.2025 15:00:00 CEST | Press release
Founded by Arm and industry partners, PSA Certified will continue to evolve under GlobalPlatform’s governance as the trusted global standard for secure connected devices GlobalPlatform announced today it will assume governance of PSA Certified, the global security certification scheme launched by Arm and key partners in 2019. In this next phase of growth, GlobalPlatform—the global standards organization for secure digital services and devices—will drive further collaboration, broader industry participation, and greater regulatory alignment for PSA Certified. Since its launch, PSA Certified has become a globally adopted framework that helps manufacturers and developers build secure connected products based on a Root of Trust. It aligns key security components—such as device identity, cryptography, attestation, and secure boot—with certification needs, regulatory requirements, and global best practices. To date, more than 250 products — spanning silicon, software, and devices—have been c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom